BofA Securities Adjusts Price Target on CeriBell to $31 From $26
BofA Securities has increased its price target for CeriBell, Inc. following the company's recent financial disclosures.
Stocks · News reference
Canaccord Genuity Maintains Buy Rating and Raises CeriBell Price Target to $33
Canaccord Genuity reaffirmed its 'Buy' rating on CeriBell and increased its price target to $33 from $26.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CeriBell, Inc. Reports Third Quarter 2026 Financial Results
CeriBell reported $29.3 million in revenue for the third quarter of 2026, representing a 30% year-over-year increase, and raised its full-year revenue outlook.
8-K filing — Ceribell, Inc. (CBLL)
Filed: 2026-11-03 AccNo: 0001193125-26-445487 Size: 652 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
CeriBell Announces Commercial Launch of Delirium Monitoring Solution
CeriBell has launched a new delirium monitoring feature for its point-of-care EEG platform, allowing for integrated seizure and delirium monitoring.
CeriBell CFO to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
CeriBell, Inc. announced that its Chief Financial Officer, Scott Blumberg, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.
TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $33.